Cited 0 times in

79 4

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib

Authors
 Jae Hoon Lee ; Jun Yong Park ; Hye Jin Choi ; Jong Doo Lee ; Hyo Jung Seo ; Kwang-Hyub Han ; Sang Hoon Ahn ; Do Young Kim 
Citation
 Liver International, Vol.31(8) : 1144~1149, 2011 
Journal Title
 Liver International 
ISSN
 1478-3223 
Issue Date
2011
Abstract
BACKGROUND: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used (18) F-2-fluoro-2-deoxyglucose ((18) F-FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC. MATERIALS AND METHODS: A total of 29 patients with HCC were included. Baseline (18) F-FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400 mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient. RESULTS: Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95% confidence interval (CI): 0.0-12.0] and 3.8 months (95% CI: 1.4-6.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, α-fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (P=0.030, P=0.024, P=0.020 and P=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (P=0.003 and P=0.026 respectively). When the patients were divided into two groups: low SUVmax (n=10; <5.00) and high SUVmax (n=19;≥ 5.00), the low SUV group showed significantly longer OS and PFS (P=0.023 and P=0.042 respectively). CONCLUSION: Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/94874
DOI
10.1111/j.1478-3231.2011.02541.x
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Nuclear Medicine
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
  feedback
Link
 http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2011.02541.x/abstract
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse